---
schema_version: "secwatch.filing_event.v1"
accession: "0001396814-22-000055"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2022-08-10T23:59:59+00:00"
generated_at: "2026-06-24T01:22:21.283460+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Pacira reports July 2022 net product sales of $50.2M; EXPAREL daily sales up 5% YoY

## Summary
- Preliminary unaudited net product sales for July 2022: $50.2M total ($40.9M EXPAREL, $8.2M ZILRETTA, $1.1M iovera°).
- EXPAREL net sales flat vs. July 2021 at $40.9M, but average daily sales up 5% on 20 vs. 21 selling days.
- ZILRETTA sales of $8.2M reflect continued early-stage growth; iovera° sales $1.1M vs. $1.0M prior year.
- CEO cites expanding EXPAREL adoption; Phase 3 lower extremity nerve block results expected in Q3 and Q4 2022.
- No FY2022 revenue or gross margin guidance provided due to ongoing COVID-19 and labor uncertainty.

## SEC filing metadata
- accession: 0001396814-22-000055
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2022-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000139681422000055/0001396814-22-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000139681422000055/pcrx-20220810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001396814-22-000055
- JSON: https://secwatch.observer/filing/0001396814-22-000055.json
- Plain text: https://secwatch.observer/filing/0001396814-22-000055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.